Bristol-Myers Squibb’s revenues rise on Celgene acquisition

BMS’ biggest seller was its multiple myeloma therapy Revlimid (lenalidomide), which it added to its portfolio following the Celgene acquisition.

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

The anti-CD38 antibody is an option for patients who have been treated with at least two prior therapies, including BMS’ Revlimid (lenalidomide) and a proteasome inhibitor such as Takeda’s

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

The 750-patrient ELOQUENT-1 trial showed that adding Empliciti (elotuzumab) to background treatment with BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone didn’t extend the time patients with newly-diagnosed ... That said, “Empliciti,

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

Sarclisa will now be available for patients with relapsed or refractor multiple myeloma who have received at least two prior therapies, including Celgene’s Revlimid (lenalidomide) and a proteasome inhibitor.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]